#USA #Waltham #Extracellular Vesicles #Everest Biolabs #biomarker discovery

Everest Biolabs and the Future of Biomarker Research

Everest Biolabs, a trailblazer in the life sciences sector, has recently received a substantial $2.1 million grant from the National Institutes of Health (NIH). This funding marks a significant milestone for the company, whose mission focuses on advancing research involving extracellular vesicles (EVs). With this support, Everest Biolabs plans to revolutionize the isolation of biomarkers, which play a key role in early disease detection and management.

The award, a Direct-to-Phase II grant from the National Institute of General Medical Sciences (NIGMS), is aimed at facilitating the development of groundbreaking automated technologies essential for EV isolation. Public interest in EVs has grown as they carry crucial proteins that can indicate various health conditions. The challenge lies in efficiently isolating these vesicles from complex biological fluids like plasma, where they can be hidden among other more abundant proteins.

Understanding Extracellular Vesicles

Extracellular vesicles are nano-sized particles released from all cell types. They play a vital role in cellular communication and, importantly, contain proteins and genetic material derived from their parent cells. This feature positions EVs as promising vehicles for biomarker discovery in clinical proteomics.

However, the concentration disparity in blood proteins complicates the detection process. Most mass spectrometers focus on proteins that provide limited diagnostic insights while missing the tissue-derived proteins that could offer critical information about pathological conditions. By focusing on EVs, researchers can bypass some of these barriers, as these vesicles can provide a cleaner, more representative snapshot of the biological states of tissues involved in various diseases.

Enhancing Isolation Techniques

The NIH funding will allow Everest Biolabs to enhance its automated and plate-based platform, which is essential for processing large volumes of samples with minimal manual handling. This is particularly significant in clinical settings where reproducibility and accuracy are paramount. The planned advancements will facilitate the automation of EV isolation, making it accessible for a broad range of laboratories.

In tandem with this technology, the company is set to develop next-generation Apex columns designed to increase the purity of EVs isolated from challenging biological matrices such as plasma. This innovation addresses a significant obstacle in conducting deep proteomic and transcriptomic studies, thereby expanding the potential applications of EV research in clinical practice.

Expert Insights

Tal Gilboa, co-founder and Head of Research at Everest Biolabs, expressed enthusiasm about the grant, stating, “The proteins that tell us the most about disease are the hardest to see in blood, and EVs are how we get to them.” Gilboa emphasized that the automated platform could enable laboratories to handle hundreds of plasma samples daily, delivering high-purity EVs in a consistent manner.

George Daaboul, CEO of Everest Biolabs, highlighted the grant's implications for the broader biomedical community, noting, “Scalable, standardized EV isolation is the foundation for everything downstream, from biomarker discovery to diagnostics and therapeutics.” This foundational work is essential for translating EV research into effective clinical tools.

Looking Ahead

Since emerging from stealth mode in November 2024, Everest Biolabs has introduced several products aimed at simplifying EV isolation and analysis, including their Ascent and Summit instruments, Apex class SEC columns, and Atlas ELISA kits. These innovations are setting new standards in research practices while facilitating the efficient handling of EVs.

With its unwavering commitment to advancing EV research, Everest Biolabs remains at the forefront of developments that could significantly impact clinical diagnostics, potentially leading to improved disease management and patient outcomes. Their continuous emphasis on developing reliable tools demonstrates the company's dedication to moving science forward while maintaining integrity in their research endeavors.

In summary, Everest Biolabs' recent $2.1 million grant from the NIH signals a robust validation of their technology and vision. By overcoming existing challenges in EV research, they are poised to enhance our understanding of disease markers, thereby transforming the landscape of diagnostic healthcare.